Loading...
•
Dec 31, 2019
Edwards Lifesciences Q4 2019 Earnings Report
Edwards Lifesciences reported robust fourth quarter performance driven by innovative technologies.
Key Takeaways
Edwards Lifesciences reported a strong fourth quarter with sales growth of 20% to $1.2 billion and adjusted EPS growth of 25% to $1.46. The company's full year sales and earnings significantly exceeded original guidance. 2020 guidance ranges increased: sales $4.6 billion to $5.0 billion; EPS $6.15 to $6.40
Q4 sales grew 20% to $1.2 billion; underlying sales grew 19%
Q4 TAVR sales grew 29%; underlying sales grew 30%
Q4 EPS was $1.32; adjusted EPS grew 25% to $1.46
Full year 2019 sales and earnings significantly exceeded original guidance
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Overall, 2020 sales guidance for Edwards is now expected to be $4.6 to $5.0 billion versus the company’s previous range of $4.5 to $5.0 billion. Additionally, the company now expects full year 2020 adjusted earnings per share of $6.15 to $6.40 versus previous guidance of $6.05 to $6.30. For the first quarter of 2020, the company projects total sales to be between $1.15 and $1.2 billion, and adjusted EPS of $1.49 to $1.59.
Positive Outlook
- 2020 sales guidance for Edwards is now expected to be $4.6 to $5.0 billion
- Full year 2020 adjusted earnings per share of $6.15 to $6.40 is expected
- For the first quarter of 2020, total sales to be between $1.15 and $1.2 billion is projected
- For the first quarter of 2020, adjusted EPS of $1.49 to $1.59 is projected
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...